Naltrexone Alone and With Sertraline for the Treatment of Alcohol Dependence in Alaska Natives and Non‐Natives Residing in Rural Settings: A Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background: Access to specialty alcoholism treatment in rural environments is limited and new treatment approaches are needed. The objective was to evaluate the efficacy of naltrexone alone and in combination with sertraline among Alaska Natives and other Alaskans living in rural settings. An exploratory aim examined whether the Asn40Asp polymorphism of the μ‐opioid receptor gene (OPRM1) predicted response to naltrexone, as had been reported in Caucasians. Methods: Randomized, controlled trial enrolling 101 Alaskans with alcohol dependence, including 68 American Indians/Alaska Natives. Participants received 16 weeks of either (1) placebo (placebo naltrexone + placebo sertraline), (2) naltrexone monotherapy (50 mg naltrexone + sertraline placebo) and (3) naltrexone + sertraline (100 mg) plus nine sessions of medical management and supportive advice. Primary outcomes included Time to First Heavy Drinking Day and Total Abstinence. Results: Naltrexone monotherapy demonstrated significantly higher total abstinence (35%) compared with placebo (12%, p = 0027) and longer, but not statistically different, Time to First Heavy Drinking Day (p = 0.093). On secondary measures, naltrexone compared with placebo demonstrated significant improvements in percent days abstinent (p = 0.024) and drinking‐related consequences (p = 0.02). Combined sertraline and naltrexone did not differ from naltrexone alone. The pattern of findings was generally similar for the American Indian/Alaska Native subsample. Naltrexone treatment response was significant within the group of 75 individuals who were homozygous for OPRM1 Asn40 allele. There was a small number of Asp40 carriers, precluding statistical testing of the effect of this allele on response. Conclusions: Naltrexone can be used effectively to treat alcoholism in remote and rural communities, with evidence of benefit for American Indians and Alaska Natives. New models of care incorporating pharmacotherapy could reduce important health disparities related to alcoholism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 1×
“Individuals were excluded who had a Clinical Institute Withdrawal Assessment – Alcohol (CIWA-Ar) (Sullivan et al., 1989) score of >8 prior to randomization, were receiving other substance abuse treatment, or required more intensive treatment.”
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Recovery from DSM‐IV alcohol dependence: United States, 2001–2002
Dawson, D. A., Grant, B. F., Stinson, F. S., Chou, P. S., Huang, B., & Ruan, W. J. (2005) · Addiction · doi:10.1111/j.1360-0443.2004.00964.x · Cited by 597
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571 · cited 3×
“These findings in a group controlled for OPRM1 genotype are consistent with the main effect of naltrexone on reduced risk of relapse even when controlling for genotype in studies by Oslin et al. (2003) and Gelernter (Gelernter et al., 2007).”
Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G
Zhang, Y., Wang, D., Johnson, A. D., Papp, A. C., & Sadée, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504942200 · Cited by 563 · cited 2×
“Based on studies (Beyer et al., 2004; Bond et al., 1998; Zhang et al., 2005) describing functional significance of a polymorphism of OPRM1, Asn40Asp (Bergen et al., 1997), several groups have investigated whether this polymorphism predicts differential response to naltrexone for the treatment of…”
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451 · cited 4×
“, 1997), several groups have investigated whether this polymorphism predicts differential response to naltrexone for the treatment of alcohol dependence (Anton et al., 2008; Gelernter et al., 2007; Oslin et al., 2003).”
InfluentialSelf-citationRecovery from alcohol problems with and without treatment: prevalence in two population surveys.
Sobell, L. C., Cunningham, J. A., & Sobell, M. B. (1996) · American Journal of Public Health · doi:10.2105/ajph.86.7.966 · Cited by 426
King, A. C., Volpicelli, J. R., Frazer, A., & O'Brien, C. P. (1997) · Psychopharmacology · doi:10.1007/s002130050156 · Cited by 227 · cited 2×
“In previous research, family history of alcoholism has predicted benefit from naltrexone (King et al., 1997; Monterosso et al., 2001; O’Malley, 1999; Rubio et al., 2005), and greater alcoholism severity was associated with recoveries involving abstinence, rather than moderation (Dawson et al.”
Beals, J., Manson, S. M., Mitchell, C. M., Spicer, P., & AI-SUPERPFP Team (2003) · Culture Medicine and Psychiatry · doi:10.1023/a:1025347130953 · Cited by 182 · cited 2×
“…about the impact alcoholism has upon their communities (Department of Health and Human Services, 2002), their interest in improving alcohol treatment effectiveness, and the under-representation of AI ⁄ANs in alcoholism treatment and related research studies (Beals et al., 2005; Shore et al., 2002).”
Cited by
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 764
Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
American Indian and Alaska Native mental health: diverse perspectives on enduring disparities
Gone, J. P., & Trimble, J. E. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143127 · Cited by 440
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“African Americans may not respond as well to naltrexone, although benefit has been shown for American Indian and Alaskan natives (O’Malley et al., 2008; Ray and Oslin, 2009) (Ib).”
Background
Metadata
- Authors
- O’Malley, S. S., Robin, R. W., Levenson, A. L., GreyWolf, I., Chance, L. E., Hodgkinson, C. A., Romano, D., Robinson, J., Meandzija, B., Stillner, V., Wu, R., & Goldman, D.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2008-06-28
- Volume
- 32
- Issue
- 7
- Pages
- 1271-1283
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- OpenAlex
- W2092837773
- Cited by
- 101
- References
- 13
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naltrexone Alone and With Sertraline for the Treatment of Alcohol Dependence in Alaska Natives and Non‐Natives Residing in Rural Settings: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1111/j.1530-0277.2008.00682.x
- The paper
- O’Malley, S. S., Robin, R. W., Levenson, A. L., GreyWolf, I., Chance, L. E., Hodgkinson, C. A., Romano, D., Robinson, J., Meandzija, B., Stillner, V., Wu, R., & Goldman, D. (2008). Naltrexone Alone and With Sertraline for the Treatment of Alcohol Dependence in Alaska Natives and Non‐Natives Residing in Rural Settings: A Randomized Controlled Trial. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2008.00682.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.